| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
1 ml |
Concentrate |
RUO |
Z2498RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
7 ml |
Ready-to-use |
RUO |
Z2498RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.5 ml |
Concentrate |
RUO |
Z2498RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.1 ml |
Concentrate |
RUO |
Z2498RT-R |
-
|
| Host |
Rabbit |
| Klon |
SP123 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
| Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
0.5 ml |
Concentrate |
RUO |
506-4232 |
-
|
| Host |
Rabbit |
| Klon |
SP123 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
| Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
1 ml |
Concentrate |
RUO |
506-4234 |
-
|
| Host |
Mouse |
| Klon |
BGN/1210/55 |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Folate binding protein from bovine milk |
Folate Binding Protein
|
Zytomed Systems GmbH |
BGN/1210/55 |
200 µg |
Purified |
RUO |
606-0136 |
-
|
| Host |
Rabbit |
| Klon |
SP88 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide derived from near C-terminus of human FOXA1 protein |
| Lokalisation |
Nuclear in prostate |
FOXA1
|
Zytomed Systems GmbH |
SP88 |
1 ml |
Concentrate |
RUO |
506-3884 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
506-19060 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
506-19062 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
506-19064 |
-
|
| Host |
Rabbit |
| Klon |
ZR333 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant Human FOXP1 protein |
| Lokalisation |
Nuclear |
FOXP1
|
Zeta Corporation |
ZR333 |
0.1 ml |
Concentrate |
CE/IVD |
Z2639RT |
-
|
| Host |
Rabbit |
| Klon |
SP97 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
| Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
0.1 ml |
Concentrate |
RUO |
506-3970 |
-
|
| Host |
Rabbit |
| Klon |
SP97 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
| Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
0.5 ml |
Concentrate |
RUO |
506-3972 |
-
|
| Host |
Rabbit |
| Klon |
SP97 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
| Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
1 ml |
Concentrate |
RUO |
506-3974 |
-
|
| Host |
Mouse |
| Klon |
86D |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
0.1 ml |
Concentrate |
CE/IVD |
ACI3197A |
-
|
| Host |
Mouse |
| Klon |
86D |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
1 ml |
Concentrate |
CE/IVD |
ACI3197C |
-
|
| Host |
Mouse |
| Klon |
236A/E7 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, melanoma |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
236A/E7 |
6 ml |
Ready-to-use |
CE/IVD |
API3164AA |
-
|
| Host |
Mouse |
| Klon |
86D |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
6 ml |
Ready-to-use |
CE/IVD |
API3197AA |
-
|
| Host |
Rabbit |
| Klon |
ZR246 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length hFSH beta sub-unit |
| Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
1 ml |
Concentrate |
CE/IVD |
Z2721RL |
-
|
| Host |
Rabbit |
| Klon |
ZR246 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length hFSH beta sub-unit |
| Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
7 ml |
Concentrate |
CE/IVD |
Z2721RP |
-
|
| Host |
Rabbit |
| Klon |
ZR246 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length hFSH beta sub-unit |
| Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
0.5 ml |
Concentrate |
CE/IVD |
Z2721RS |
-
|
| Host |
Rabbit |
| Klon |
ZR246 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length hFSH beta sub-unit |
| Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
0.1 ml |
Concentrate |
CE/IVD |
Z2721RT |
-
|
| Host |
Mouse |
| Klon |
BGN/F63/02 |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Intact Follicle Stimulating Hormone |
FSH (Follicle Stimulating Hormone)
|
Zytomed Systems GmbH |
BGN/F63/02 |
1 mg |
Purified |
RUO |
606-0161 |
-
|
| Host |
Mouse |
| Klon |
GAL3-3B8 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Papillary thyroid carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3174A |
-
|
| Host |
Mouse |
| Klon |
GAL3-3B8 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Papillary thyroid carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3174B |
-
|
| Host |
Mouse |
| Klon |
GAL3-3B8 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Papillary thyroid carcinoma |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
6 ml |
Ready-to-use |
CE/IVD |
API3174AA |
-
|
| Host |
Mouse |
| Klon |
H-5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
1 ml |
Concentrate |
CE/IVD |
MOB541 |
-
|
| Host |
Mouse |
| Klon |
H-5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
colon carcinoma, papillary thyroid carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB541-01 |
-
|
| Host |
Mouse |
| Klon |
H-5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB541-05 |
-
|
| Host |
Mouse |
| Klon |
H-5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoms |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM541 |
-
|
| Host |
Mouse |
| Klon |
H-5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
25 ml |
Ready-to-use |
CE/IVD |
PDM541-25 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM182 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Papillary or follicular thyroid carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
1 ml |
Concentrate |
CE/IVD |
Z2487ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM182 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Papillary or follicular thyroid carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
7 ml |
Ready-to-use |
CE/IVD |
Z2487MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM182 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Papillary or follicular thyroid carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
0.5 ml |
Concentrate |
CE/IVD |
Z2487MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM182 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Papillary or follicular thyroid carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
| Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
0.1 ml |
Concentrate |
CE/IVD |
Z2487MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR027 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP044 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP044-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP044-05 |
-
|
| Host |
Mouse |
| Klon |
ZM359 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Normal gastric mucosa |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human GAST protein |
| Lokalisation |
Cytoplasm |
Gastrin
|
Zeta Corporation |
ZM359 |
7 ml |
Ready-to-use |
CE/IVD |
Z2735MP |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
| Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
1.0 ml |
Concentrate |
CE/IVD |
Z2227ML |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
| Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
7 ml |
Ready-to-use |
CE/IVD |
Z2227MP |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
| Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
0.5 ml |
Concentrate |
CE/IVD |
Z2227MS |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
| Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
0.1 ml |
Concentrate |
CE/IVD |
Z2227MT |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
7 ml |
Ready-to-use |
CE/IVD |
ALI405G7 |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
0.1 ml |
Concentrate |
CE/IVD |
CM405A |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
0.5 ml |
Concentrate |
CE/IVD |
CM405B |
-
|
| Host |
Mouse |
| Klon |
L50-823 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
6 ml |
Ready-to-use |
CE/IVD |
PM405AA |
-
|
| Host |
Mouse + Mouse |
| Klon |
L50-823 + BC21 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Bladder cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa + Mouse IgG1 kappa |
| Lokalisation |
Nuclear + Cytoplasmic/membrane |
GATA3 + Uroplakin II
|
Biocare Medical |
L50-823 + BC21 |
6 ml |
Ready-to-use |
CE/IVD |
API3173AA |
-
|